Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Sep;21(9):401-4.
doi: 10.1016/S1607-551X(09)70141-X.

Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease

Affiliations

Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease

Sara Kashef et al. Kaohsiung J Med Sci. 2005 Sep.

Abstract

The purpose of this study was to determine the initial rates of intravenous gamma-globulin treatment (IVIG) failure in Kawasaki disease (KD) and their predisposing factors. This study was a retrospective analysis of the initial response to IVIG (2 g/kg), assessed from the medical reports of all patients admitted to Namazee Hospital pediatric ward, from March 1998 to March 2002, and who fulfilled the criteria for KD. Data were available for 64 patients, 58 of whom (90.6%) became afebrile 48 hours after completion of the initial dose of IVIG (Group I) and six (9.4%) who remained febrile (Group II). Two patients had a prompt response to a second dose of IVIG. In Group I, five patients (8.6%) developed coronary artery disease, seen on echocardiography. In Group II, two patients (33.3%) developed coronary artery disease. No significant difference was found in the prevalence of coronary artery disease between the two groups (p = 0.12), or in age or gender. The rate of initial treatment failure was 9.4% in this cohort of patients, which is comparable with previous reports. No predictive factors such as coronary artery disease, age or gender were found for initial treatment failure in KD.

PubMed Disclaimer

References

    1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J Allergy. 1967; 16: 178–222. - PubMed
    1. Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome prevailing in Japan. Pediatrics. 1974; 54: 271–276. - PubMed
    1. Hashino K, Ishii M, Iemura M, et al. Re‐treatment for immune globulin‐resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001; 43: 211–217. - PubMed
    1. Kato H, Koike S, Yamamoto M, et al. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr. 1975; 86: 892–898. - PubMed
    1. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979; 63: 175–179. - PubMed

Substances